CEL-SCI Corp. CVM 深 沪
等待开盘 09-25 09:30:00 美东时间
8.98
+0.350
+4.06%
华盛通- 最 高9.0999
- 今 开8.79
- 成交量 5.92万股
- 最 低 8.63
- 昨 收 8.63
- 总市值 4611.23万
- 52周最高 32.70
- 市盈率 静 --
- 换手率 1.15%
- 52周最低 1.98
- 委 比 -33.33%
- 总股本 513.50万
- 历史最高 1425.00
- 量 比 0.26
- 振 幅 5.44%
- 历史最低 5.40
- 每 手 1
- 风险率 8.27%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多蔚来资本入局！海德氢能完成新一轮战略融资
全球绿电制氢领域的领先企业海德氢能（HydoTech）今日宣布完成新一轮战略融资，由蔚来资本等机构投资，老股东襄禾资本、愉悦资本持续加码，其中，蔚来资本的部分投...
09-15 15:49
首发｜海德氢能完成新一轮战略融资，专注绿电制氢
原标题：首发｜海德氢能完成新一轮战略融资，专注绿电制氢 投资界（ID：pedaily2012）9月15日消息，绿电制氢领域企业海德氢能（HydoTech）今日...
09-15 10:53
Aura Minerals to Delist From Toronto Exchange, Consolidate Trading on Nasdaq
Aura Minerals Inc. (NASDAQ:AUGO) (TSX:ORA) (B3: AURA33) ("Aura" or the "Company") today announced that its application for a voluntary delisting (the "Delisting") of its common shares (each a "Common Share") from the
09-08 18:10
Reported Saturday, BridgeBio's Attruby/BEYONTTRA Reports Significant 42-Month CV Mortality Reduction In ATTRibute-CM Open Label Extension
- Acoramidis demonstrated a significant reduction in risk of CVM through 42 months post-randomization, with a 44% hazard reduction, setting a new standard for CVM outcomes for patients with ATTR-CM- Acoramidis also
09-02 15:50
中金：维持信达生物跑赢行业评级 上调目标价至118.3港元
中金发布研报称，考虑到信达生物（01801）上半年运营盈利能力超预期，上调2025年净利润预测84.3%至8.71亿元，基本维持2026年归母净利润预测1...
08-29 11:59
CEL-SCI股价重挫逾30%，此前宣布完成1000万美元公开发行定价
美股周四早盘，生物技术公司CEL-SCI（CVM）股价重挫30.44%，此前该公司宣布完成1000万美元公开发行定价，以每股9.00美元的价格出售1111...
08-28 22:51
Why Snowflake Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
Shares of Snowflake Inc. (NYSE:SNOW) rose sharply in pre-market trading after t...
08-28 17:48
Why Is CEL-SCI Stock Crashing After-Hours?
CEL-SCI's shares dropped 38.19% after announcing a $10 million public offering priced below market value to fund its cancer immunotherapy development.
08-28 15:12
CEL-SCI shares drop on proposed public offering
CEL-SCI Corporation (NYSE:CVM) said on Wednesday that it intends to offer to sell shares of its common stock in a best-efforts public offering. All of the shares of common stock are being offered by...
08-28 05:32
CEL-SCI Announces Proposed Public Offering; No Size Or Amount Disclosed
CEL-SCI Corporation ("CEL-SCI" or the "Company") (NYSE:CVM), a clinical stage cancer immunotherapy company,today announced that it intends to offer to sell shares of its common stock (and/or pre-funded warrants
08-28 05:26
